logo
TakedaPresentsNewDataShowingMezagitamab(TAK-079)SustainedEffectonKidneyFunction18MonthsAfterTreatmentinPrimaryIgANephropathy
===2025/11/10 15:13:58===
nts: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase
=*=*=*=*=*=
当前为第12/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页